- Home
- ECBK vs ANTX Comparison
ECBK vs ANTX Comparison
Compare ECBK & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | ANTX |
|---|---|---|
| Founded | 1919 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.6M | 170.7M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ECBK | ANTX |
|---|---|---|
| Price | $19.18 | $4.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 6.8K | ★ 193.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | 32.56 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.76 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $1.00 |
| 52 Week High | $20.05 | $6.91 |
Technical Indicators
Market Signals| Indicator | ECBK | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 63.59 |
| Support Level | $17.64 | $1.06 |
| Resistance Level | $20.05 | $5.13 |
| Average True Range (ATR) | 0.47 | 0.37 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 79.12 | 92.70 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.